Lupeol

• UNSPSC Description:

  Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC)[1].

• Target Antigen:

  Androgen Receptor; Apoptosis

• Type:

  Natural Products

• Related Pathways:

  Apoptosis;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Lupeol.html

• Purity:

  98.0

• Solubility:

  DMSO : 2 mg/mL (ultrasonic)|Ethanol : 14.29 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  C[C@]1([C@@]2(CC[C@@]3([H])C4(C)C)C)[C@@](CC[C@]2([H])[C@]3(CC[C@@H]4O)C)([H])[C@]([C@@H]5C(C)=C)([H])[C@](C)(CC5)CC1

• Molecular Weight:

  426.72

• References & Citations:

  [1]Siddique HR, et al. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15;17(16):5379-91.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  545-47-1